🟢 Strong Evidence
A randomised controlled trial published in JACC: Heart Failure in 2014 found that ubiquinone supplementation significantly reduced hospitalisation and mortality in patients with chronic heart failure. The Q-SYMBIO trial enrolled 420 patients across 17 cardiology centres in nine countries and followed them for two years, comparing 100 mg of ubiquinone (coenzyme Q10) three times daily added to standard therapy against placebo.
Key takeaways
- CoQ10 supplementation reduced serious cardiac events by 43% relative to placebo in patients with moderate to severe heart failure
- Cardiovascular mortality fell from 16% in the placebo group to 9% in the CoQ10 group, a 44% relative reduction
- The supplement was added to guideline-directed medical therapy, not as replacement treatment
- All clinically meaningful endpoints—hospitalisations, mortality, transplant need—moved in the same favourable direction
Study at a Glance
| Source | JACC: Heart Failure |
| Study type | Randomised controlled trial |
| Sample size | N = 420 |
| Population | Patients with moderate to severe chronic heart failure already on guideline-directed medical therapy |
| Intervention | Ubiquinone 100 mg three times daily for 24 months versus placebo |
| Countries | Nine countries, 17 cardiology centres |
Clinical outcomes in Q-SYMBIO trial: CoQ10 versus placebo at two years
Percentage of patients experiencing primary endpoint and key secondary endpoints
Source: Q-SYMBIO trial, JACC: Heart Failure, 2014 | Georgian Medical Journal News
Trial design: CoQ10 as adjunct to standard care
The Q-SYMBIO trial, conducted by Mortensen and colleagues across nine countries, enrolled 420 patients with moderate to severe chronic heart failure who were already receiving guideline-directed medical therapy. Patients were randomised to receive either 100 mg of ubiquinone (CoQ10) three times daily or matching placebo for 24 months. Critically, the supplement was added to, not substituted for, optimal medical management.
The primary composite endpoint was unplanned heart failure hospitalisation, cardiovascular death, urgent transplant, or need for mechanical circulatory support. Secondary endpoints included cardiovascular mortality, all-cause mortality, and heart failure hospitalisations. By measuring hard clinical events rather than biomarkers, the trial captured clinically meaningful outcomes that matter to patients.
Robust reductions across all cardiac endpoints
At two years, the trial demonstrated consistent benefit across every measured outcome. According to the published data in JACC: Heart Failure, 15% of CoQ10-treated patients met the primary endpoint compared with 26% in the placebo group—a 43% relative risk reduction. This effect size would typically qualify a pharmaceutical intervention for accelerated regulatory review.
Cardiovascular mortality showed an even sharper separation: 9% in the CoQ10 arm versus 16% in placebo, representing a 44% relative reduction. All-cause mortality fell from 18% to 10% (a 44% reduction), and heart failure hospitalisations decreased from 14% to 8%. The consistency of benefit across endpoints strengthens confidence in the overall finding, as it reduces the likelihood of random variation driving a single favourable result.
Over two years, CoQ10 supplementation at 100 mg three times daily reduced the composite of cardiovascular death, heart failure hospitalisation, urgent transplant, or mechanical support by 43% relative to placebo in patients with moderate to severe heart failure on optimal medical therapy.
— Mortensen et al., JACC: Heart Failure, 2014
Mechanism: restoring mitochondrial energy production
The biological rationale for CoQ10 efficacy in heart failure rests on its central role in mitochondrial energy metabolism. CoQ10 functions as an electron shuttle within the respiratory chain, transferring electrons from Complex I and Complex II to Complex III. This electron flow drives the proton gradient across the inner mitochondrial membrane, which powers ATP synthesis—the fundamental energy currency of the cell. Heart failure is, in part, a disease of impaired myocardial energy production, making mitochondrial dysfunction a plausible therapeutic target.
Chronic heart failure is associated with reduced myocardial CoQ10 levels and impaired mitochondrial function. By supplementing with ubiquinone, the Q-SYMBIO trial tested whether restoring this critical cofactor could improve energy availability in failing cardiac tissue. The magnitude of clinical benefit observed aligns with this mechanistic hypothesis, though the trial did not measure mitochondrial function or tissue CoQ10 levels directly.
Clinical interpretation and current evidence landscape
The Q-SYMBIO trial represents the most rigorous evidence base for CoQ10 supplementation in cardiovascular disease to date, published in a peer-reviewed cardiology journal and employing a double-blind, placebo-controlled design with hard clinical endpoints. However, several factors warrant careful interpretation. First, the trial enrolled only patients with moderate to severe heart failure; findings may not generalise to milder disease or to prevention in asymptomatic individuals. Second, ubiquinone was studied as an adjunct to standard therapy, not as monotherapy, meaning the benefit cannot be attributed to CoQ10 alone.
Despite the trial’s strength, CoQ10 remains underutilised in routine heart failure management, and many practitioners remain unaware of the Q-SYMBIO findings. Coverage by health insurance and regulatory approval as a therapeutic agent vary widely by jurisdiction. The supplement continues to be marketed primarily as a dietary supplement rather than as a pharmacological agent, a distinction with implications for quality control, manufacturing standards, and clinical integration.
What this means
Frequently asked questions
Does CoQ10 work for all types of heart failure?
The Q-SYMBIO trial tested patients with moderate to severe chronic heart failure and did not separate results by ejection fraction type (HFrEF, HFpEF, or HFmrEF). Efficacy in milder disease or in asymptomatic individuals with reduced ejection fraction has not been established. CoQ10 was studied as an adjunct to guideline-directed care, not as monotherapy.
What dose was used in the trial, and is it safe?
The Q-SYMBIO trial used 100 mg three times daily (300 mg total) for 24 months. CoQ10 is generally well tolerated at this dose; reported adverse events in the trial were similar between groups. However, ubiquinone has lipophilic properties and may interact with warfarin and other medications. Always inform your doctor before starting supplementation.
Why isn’t CoQ10 more widely prescribed if the evidence is so strong?
Several factors limit adoption: CoQ10 is regulated as a dietary supplement in many countries, not a pharmaceutical drug, affecting manufacturing oversight; cardiovascular guidelines were published before or shortly after Q-SYMBIO and have not universally incorporated the findings; and regulatory pathways differ between nations. Additionally, cost-effectiveness analyses and long-term safety data beyond two years remain limited.
The Q-SYMBIO trial demonstrates that a simple, well-tolerated supplement can produce clinically significant reductions in cardiovascular death and hospitalisation when added to optimal heart failure therapy. As guidelines evolve and awareness increases, CoQ10 supplementation may become standard adjunctive care for patients with symptomatic heart failure who remain limited despite guideline-directed medications. Further trials investigating dose optimisation, long-term safety, and application in other cardiovascular conditions would strengthen the evidence base and help define CoQ10’s place in modern cardiology. For now, the Q-SYMBIO data provide robust justification for discussing this intervention with appropriately selected heart failure patients.
Source: Q-SYMBIO trial: ubiquinone supplementation and cardiovascular outcomes in heart failure
Was this article helpful?
Disclaimer. This article is health journalism intended for general information and education. It is not medical advice and is not a substitute for professional diagnosis or treatment. Always consult a qualified healthcare provider about your individual circumstances. Full disclaimer →
Related Coverage
Medically reviewed by Prof. Giorgi Pkhakadze, MD, MPH, PhD. Spotted an error? Contact the editorial team.
